Latest B-cell chronic lymphocytic leukemia Stories
A new study has discovered how resistance develops in patients taking ibrutinib, a new and highly effective drug for the treatment of chronic lymphocytic leukemia (CLL).
A multi-institutional team of researchers has pinpointed exactly what goes wrong when chronic lymphocytic leukemia (CLL) patients develop resistance to ibrutinib, a highly effective, precisely targeted anti-cancer drug.
TG02 also shown to be equally active in CLL cells from patients prior to and following twelve months of ibrutinib therapy. San Diego (PRWEB) May 28, 2014
RnRMarketResearch.com adds “EpiCast Report Amyotrophic Lateral Sclerosis & Chronic Lymphocytic Leukemia – Epidemiology Forecast to 2023” to its store.
- Research in hematological malignancies features: ibrutinib (IMBRUVICA®), siltuximab (SYLVANT(TM)) and daratumumab; research in solid tumors features: abiraterone acetate (ZYTIGA®), ARN-509, trabectedin
Having successfully Pioneered Robotic Surgery, Robert "Bob" Duggan Is Giving Hope to Cancer Patients Through His Innovative Biotech Company SUNNYVALE, Calif., May 7, 2014 /PRNewswire-iReach/
First full quarter after launch of IMBRUVICA(TM) net product revenue of $56.2 million SUNNYVALE, Calif., May 2, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
- Investigators to Present Clinical Trial Findings Evaluating Compounds in Multiple Tumor Types NORTH CHICAGO, Ill., April 23, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that
FLINT, Mich., April 22, 2014 /PRNewswire-iReach/ -- The US Food and Drug Administration has announced the expanded approval of Arzerra(®) (ofatumumab) in combination with chlorambucil for
SUNNYVALE, Calif., April 21, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
- A person or thing gazed at with wonder or curiosity, especially of a scornful kind.